| Literature DB >> 31597949 |
A D Anastasiou1,2, M Nerantzaki3,4, E Gounari5, M S Duggal6, P V Giannoudis7, A Jha8, D Bikiaris4.
Abstract
Scaffolds and implants in orthopaedics and regenerative dentistry usually fail because of bacterial infections. A promising solution would be the development of biomaterials with both significant regenerative potential and enhanced antibacterial activity. Working towards this direction, fluorapatite was synthesised and doped with Sr2+ and Ce3+ ions in order to tailor its properties. After experiments with four common bacteria (i.e. E. Coli, S. Aureus, B. Subtilis, B. Cereus), it was found that the undoped and the Ce3+ doped fluorapatites present better antibacterial response than the Sr2+ doped material. The synthesised minerals were incorporated into chitosan scaffolds and tested with Dental Pulp Stem Cells (DPSCs) to check their regenerative potential. As was expected, the scaffolds containing Sr2+-doped fluorapatite, presented high osteoconductivity leading to the differentiation of the DPSCs into osteoblasts. Similar results were obtained for the Ce3+-doped material, since both the concentration of osteocalcin and the RUNX2 gene expression were considerably higher than that for the un-doped mineral. Overall, it was shown that doping with Ce3+ retains the good antibacterial profile of fluorapatite and enhances its regenerative potential, which makes it a promising option for dealing with conditions where healing of hard tissues is compromised by bacterial contamination.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31597949 PMCID: PMC6785562 DOI: 10.1038/s41598-019-50916-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Synthesized materials and expected chemical formulas.
| Code name | Sr % mol. | Ce % mol. | Chemical formula |
|---|---|---|---|
| FAP | — | — | Ca10(PO4)6F2 |
| FAP-Sr | 5 | — | Ca9.5Sr0.5(PO4)6F2 |
| FAP-Ce | — | 5 | Ca4.75Ce0.25(PO4)3F1.5O0.5 |
Fabricated chitosan scaffolds.
| Code name | Chitosan to acetic acid ratio | Filler mineral (ratio based on the chitosan) |
|---|---|---|
| CH | No fillers | |
| CHFAP | 20% w/w FAP | |
| CHFAP-Sr | 20% w/w FAP-Sr | |
| CHFAP-Ce | 20% w/w FAP-Ce |
Primers designing for qPCR.
| Gene | Forward Primer | Reverse primer |
|---|---|---|
| β-actin | atctggcaccacaccttctacaatgagctgcg | cgtcatactcctgcttgctgatccacatctgc |
| RUNX2 | ttacttacaccccgccagt c | tatggagtgctgctggtctg |
Figure 1X-ray diffraction patterns of the fluorapatite minerals and comparison with a reference pattern for fluorapatite.
Figure 2FTIR patterns of the fabricated materials; (a) patterns for the fluorapatite minerals (wavenumber range 300–1500 cm−1; (b) patterns of the chitosan scaffolds with and without minerals (wavenumber range 400–4000 cm−1).
Figure 3SEM images of the synthesised fluorapatite minerals (powder form); (a) un-doped fluorapatite (FAP); (b) 5% Sr doped fluorapatite (FAP-Sr); (c) 5% Ce doped fluorapatite (FAP-Ce).
Figure 4Typical SEM images of the chitosan scaffolds (images from the CHFAP-Ce). (a) Porosity at the surface of the scaffold; (b) distribution of the mineral nanoparticles in the scaffold; (c) mineral nanoparticles at higher magnification; (d) typical EDX maps of Ca and Ce.
Figure 5Mass loss of minerals after 48 h in a phosphate buffer (3 pellets of each mineral were tested, with initial mass of 0.25 g/pellet).
Half maximal inhibitory concentration (IC50) value of FAP, FAP-Sr and FAP-Ce for E. coli, S. aureus, B. subtilis and B. cereus.
| FAP | 110 ± 7.5 | 112 ± 6.2 | 119 ± 7.3 | 156 ± 10.1 |
| FAP-Sr | 141 ± 6.0 | 149 ± 10.1 | 191 ± 11.2 | 239 ± 13.1 |
| FAP-Ce | 107 ± 7.1 | 135 ± 9.3 | 133 ± 8.1 | 165 ± 11.5 |
Figure 6Interaction of the fabricated scaffolds with DPSCs. (a) Measurements of metabolic activity (MTT assay); SEM micrographs of the DPSCs on (b) CH, (c) CHFAP, (d) CHFAP-Sr) and (e) CHFAP-Ce scaffolds. Cells migrate from the culture media and occupy the pores of the scaffold (scale bars of 70 μm).
Figure 7Differentiation of the DPSCs to osteoblasts. (a) Concentration of osteocalcin on each scaffold. (b) Expression of RUNX2 gene.